Working… Menu
Trial record 35 of 232 for:    yeast

Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01028274
Recruitment Status : Completed
First Posted : December 9, 2009
Last Update Posted : December 14, 2015
Nutrasource Diagnostics Inc.
Information provided by (Responsible Party):
Nordic Pharma, USA

Brief Summary:
The purpose of this study is to assess the safety and efficacy of a natural health product among participants with elevated LDL cholesterol and triglyceride levels.

Condition or disease Intervention/treatment Phase
LDL Cholesterol Triglycerides Dietary Supplement: Placebo Dietary Supplement: Investigational Product 1 Dietary Supplement: Investigational Product 2 Phase 1 Phase 2

Detailed Description:

Cardiovascular Disease [CVD] is one of the primary causes of illness, disability and death in Canada and in the United States. Hypercholesterolemia and hypertriglyceridemia are significant risk factors for the development of cardiovascular disease.

The investigational product used in this trial, has been specially formulated to help reduce elevated triglycerides and LDL cholesterol levels, and may provide a natural alternative in the prevention of CVD.

This study is a prospective, 12 week study, where participants will be randomized to receive the treatment, placebo, or a comparator product for a period of 12 weeks. Blood lipids will be analysed at baseline, week 6 and week 12.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 148 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Trial to Assess the Safety and Efficacy of a Combination Red Yeast Rice and Omega-3 (EPA+DHA) to Reduce LDL Cholesterol and Triglyceride Levels in Hypercholesterolemic and Hypertriglyceridemic Subjects.
Study Start Date : September 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo Dietary Supplement: Placebo
Two capsules, twice daily with meals for 12 weeks.
Other Names:
  • Soybean Oil
  • Mfr. Product Code: 31237-NNM

Experimental: Investigational Product 1 Dietary Supplement: Investigational Product 1
Two capsules, twice daily with meals for 12 weeks.
Other Name: Mfr. Product Code: 31214-NNM

Experimental: Investigational Product 2 Dietary Supplement: Investigational Product 2
Two capsules, twice daily with meals for 12 weeks.
Other Name: Mfr. Product Code: 31236-NNM

Primary Outcome Measures :
  1. Reduction in LDL levels [ Time Frame: 0 weeks, 6 weeks, 12 weeks ]

Secondary Outcome Measures :
  1. Reduction in TG levels [ Time Frame: 0 weeks, 6 weeks, 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adults aged 30 - 70 years.
  • 10-year CAD Risk <10%
  • Elevated blood LDL cholesterol in the range of 3.0 to 5.0 mmol/L [equivalent to 117-195 mg/dl].
  • have elevated TG levels [1.5/L - 4.0mmol/L, or 134 mg/dl - 356 mg/dl].

Exclusion Criteria:

  • Adults aged less than 30, or more than 70 years of age
  • Adults with a 10-year CAD risk >10%
  • Individuals with a pre-existing disease or illness including: heart disease, diabetes, renal disease or cancer
  • Individuals taking CYP3A4 inhibitors [including cyclosporine and danazol].
  • Individuals taking Statin medications, including: Atorvastatin [brand names: Lipitor®, Caduet®]

    • Fluvastatin [brand names: Lescol®, Lescol® XL]
    • Lovastatin [brand names: Advicor ®, Altocor ®, Altoprev ®, Mevacor ®]
    • Pravastatin [brand names: Pravachol® , Pravigard® PAC]
    • Rosuvastatin [brand name: Crestor®]
    • Simvastatin [brand names: Vytorin®, Zocor ®]
  • Individuals with an allergy to fish and/or fish oil, Vitamin E, red yeast rice, coenzyme Q10, soybean oil or any other ingredient in the investigational product [i.e. capsule constituents]
  • Individuals who anticipate, or have planned surgery during the course of the trial
  • Individuals who are taking any other natural health products, particularly those containing vitamin K, high levels of vitamin E or Coenzyme Q10 [individuals on a 4-week wash-out of NHPs will be permitted]
  • Individuals who have consumed fish oil or another type of omega-3 fatty acid supplement one-month prior-to and/or during the course of the study
  • Women who are pregnant or breastfeeding
  • Individuals with a history of migraines
  • Individuals taking blood thinning, or blood pressure medications
  • Individuals who have been diagnosed with statin-induced muscle damage (myopathy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01028274

Layout table for location information
Canada, Ontario
Nutrasource Diagnostics Inc.
Guelph, Ontario, Canada, N1G0B4
Sponsors and Collaborators
Nordic Pharma, USA
Nutrasource Diagnostics Inc.
Layout table for investigator information
Study Director: Maggie Laidlaw, Ph.D. Candidate Nutrasource Diagnostics Inc.
Study Chair: Brad West, ND Nordic Naturals
Principal Investigator: Steven Traplin, MD Nutrasource Diagnostics Inc.

Layout table for additonal information
Responsible Party: Nordic Pharma, USA Identifier: NCT01028274     History of Changes
Other Study ID Numbers: NN-91109
First Posted: December 9, 2009    Key Record Dates
Last Update Posted: December 14, 2015
Last Verified: December 2015
Keywords provided by Nordic Pharma, USA:
Fish Oil
Red Yeast Rice
Additional relevant MeSH terms:
Layout table for MeSH terms
Red yeast rice
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents